HBC Hofseth Biocare

Hofseth Biocare ASA: SECURES DISTRIBUTION WITH A GLOBAL RETAILER GIANT IN THE UK, SPAIN, ICELAND, AND ONLINE FOR BRILLIANT SALMON OILâ„¢ FOR PETS

Hofseth Biocare ASA: SECURES DISTRIBUTION WITH A GLOBAL RETAILER GIANT IN THE UK, SPAIN, ICELAND, AND ONLINE FOR BRILLIANT SALMON OIL™ FOR PETS

Hofseth BioCare ASA (“HBC”) pet care product Brilliant Salmon Oil™, a food and health supplement for dogs and cats, is now available in outlets across the UK, Spain, Iceland and online.

This retail distribution agreement with a global leading club store is an important milestone for HBC in its efforts for global distribution of Brilliant Salmon Oil™. The launch has started very successfully, and in-store incentive promotions will start at the end of the month to raise even more awareness. 

Kai Morten Thuen, Hofseth BioCare ASA’s Head of Sales & Marketing states, “This is an honor and great recognition for our company. We are thrilled to enter this retail agreement with one of the most well-renowned global retailers, known for their rigorous quality standards. It further accelerates our growth strategy for our pet care market flagship product, Brilliant Salmon Oil.”

Furthermore, in the last three months, HBC has signed up seven more distributors in the US and Canada, covering most of North America.  Brilliant Salmon Oil™ first entered a US store in April of this year and will be available in over 1,000 stores by the end of September. The speed of this success, despite a COVID-19 market slowdown, is seen as very encouraging and outpaces our expectations. 

About Brilliant Salmon Oil:

Brilliant Salmon Oil by Hofseth BioCare is produced in Norway using the purest process possible. Due to the unique patented extraction process – without boiling or pressing the oil – all the natural nutrients in the Atlantic Salmon are preserved. The whole process happening within hours, result in the purest and most transparent oil, completely free of additives. Brilliant contributes to shinier coat, softer paws, as well as helping to prevent cardiovascular disease. 

For further information, please contact:

Kai Morten Thuen, Head of Sales and Marketing at Hofseth BioCare ASA

Phone:

E-mail:

James Berger, Head of Investor Relations & Strategy at Hofseth BioCare ASA

Phone:

E-mail:

About Hofseth BioCare ASA:

HBC is a Norwegian biotech company that develops high-value ingredients and finished products. The ingredients are in various stages of discovery and preclinical development in collaboration with multiple clinics and university research labs in several countries. Lead preclinical and clinical candidates are in development toward treatment for iron-deficiency anaemia, Gastro-Intestinal Inflammation (NEC/IBS/UC), prediabetes, age-related sarcopenia and osteoarthritis.

The company is founded on the core values of sustainability, traceability and optimal utilization of natural resources. Through an innovative hydrolysis technology, HBC can preserve the quality of lipids, proteins and calcium from fresh salmon off-cuts. Hofseth BioCare's headquarters are in Ålesund, Norway with branches in Oslo, London, Zürich, Chicago, Menlo Park and Tokyo.

HBC is listed on Oslo Stock Exchange Axess list with ticker "HBC". More information about Hofseth BioCare at hofsethbiocare.com and facebook.com/hofsethbiocare



This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act

EN
27/08/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Hofseth Biocare

 PRESS RELEASE

Hofseth BioCare ASA: Cancellation of Subsequent Offering – Update on c...

Hofseth BioCare ASA: Cancellation of Subsequent Offering – Update on completion of Private Placement NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to previous announcements by Hofseth BioCare ASA (the "Company") regarding a subsequent offering with gross proceeds of up to approx. NOK 30,000,000 throug...

 PRESS RELEASE

Hofseth BioCare ASA: PRIMARY INSIDER NOTIFICATION

Hofseth BioCare ASA: PRIMARY INSIDER NOTIFICATION Christoph Baldegger, primary insider and member of the Board of Directors in Hofseth BioCare ASA ("HBC"), has subscribed for 368,320 Offer shares in the Subsequent Offering and Mr. Baldegger will hold 3,616,296 shares in HBC after the share capital is registered, equal to approximately 0.92 % of the total outstanding A-shares with voting rights.  For further information, contact: Jon Olav Ødegård, CEO of Hofseth BioCare ASA Phone: E-mail: This information is subject to the disclosure requirements in the Market Abuse Regulation EU 596/20...

 PRESS RELEASE

Hofseth BioCare ASA: RESULTS OF SUBSEQUENT OFFERING

Hofseth BioCare ASA: RESULTS OF SUBSEQUENT OFFERING NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to previous announcements by Hofseth BioCare ASA (the "Company") regarding a subsequent offering with gross proceeds of up to approx. NOK 30,000,000 through issuance of up to 16,666,666 new ordinary share...

 PRESS RELEASE

Hofseth BioCare ASA: Extraordinary General Meeting completed

Hofseth BioCare ASA: Extraordinary General Meeting completed Hofseth BioCare ASA held an Extraordinary General Meeting on 20 November 2025. All proposals were resolved as presented in the notice issued on 30 October 2025. The minutes from the Extraordinary General Meeting are attached. For further information, please contact:Jon Olav Ødegård, CEO at HBCE-mail: About Hofseth BioCare ASA: HBC is a Norwegian consumer and pet health company founded on the core values of sustainability, optimal utilization of natural resources and full traceability. It upcycles the side streams of the salmo...

 PRESS RELEASE

Hofseth BioCare ASA: LAST DAY OF SUBSCRIPTION PERIOD IN SUBSEQUENT OFF...

Hofseth BioCare ASA: LAST DAY OF SUBSCRIPTION PERIOD IN SUBSEQUENT OFFERING NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to the stock exchange announcements by Hofseth BioCare ASA ("HBC" or the "Company") on 7 November 2025 regarding the terms of a subsequent offering of up to 16,666,666 new shares (...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch